CA-POINT2WEB
31.7.2024 18:54:28 CEST | Business Wire | Press release
Point2Web, your ultimate marketing powerhouse in creative, advertising, and performance marketing, is thrilled to announce its appointment as the first Agency Sales Partner in Europe for NewsBreak, America's leading platform for local news and information, with over 40 million monthly active users.
Together, Point2Web and NewsBreak are poised to deliver exceptional advertising solutions that deeply engage local audiences. This partnership aims to drive significant growth and performance for Point2Web clients by combining the strengths of both companies to create something truly groundbreaking. The collaboration is expected to foster innovation, enhance service excellence, and achieve positive results for NewsBreak’s local users and their communities across America.
By utilizing NewsBreak's innovative technology and unrivaled local footprint, brands can revolutionize their local and targeted advertising and help direct resources where they are needed most. Point2Web's industry-leading expertise will further enable clients to amplify their advertising impact on an unprecedented scale. The collaboration will be particularly beneficial to advertisers in insurance, finance, travel, home improvement, e-commerce, and casual gaming, among others.
Partnership Highlights:
- Extended Reach: Point2Web clients will now have access to NewsBreak's 40 million users across the U.S., significantly enhancing the impact of their advertising campaigns. This access ensures advertisers can reach a vast yet highly engaged user base.
- Innovative Solutions: The partnership brings NewsBreak's use of new technology to Point2Web's clientele.
- Global Expertise, Local Impact: Point2Web's global presence and deep expertise in performance networks, combined with NewsBreak's robust local information platform, ensures a targeted and effective advertising strategy that will resonate with local communities. This synergy enables advertisers to craft messages that are both globally informed and locally relevant.
- Fostering Innovation and Achieving Success: Both Point2Web and NewsBreak share a strong commitment to innovation, excellence in service, and achieving positive results for their stakeholders. This partnership is a testament to their joint vision of pushing the boundaries of what is possible in digital advertising.
“Through our partnership with NewsBreak, we’re not just expanding the digital footprint of our clients; we’re providing them with the tools and platforms necessary to achieve unprecedented levels of engagement and success in their advertising campaigns,” said Valentine Kovalenko, COO at Point2Web. “This collaboration is a testament to our unwavering commitment to innovation and excellence in service. NewsBreak’s audience is highly engaged and of high quality, which ensures that our clients' ads reach a valuable and responsive demographic.”
“We are thrilled to partner with Point2Web, whose global expertise and innovative approach align perfectly with our mission to create a local media ecosystem where information is readily available and easily accessible," said Ryan Ludlow, General Manager of NewsBreak Advertising. "By leveraging our cutting-edge new technology and working with strategic partners like Point2Web, we remain dedicated to enhancing advertiser success and maintaining our focus on ad quality.”
For more information about this partnership and how it can benefit your advertising strategies, please visit our website.
About Point2Web
Point2Web is a global advertising agency that specializes in performance marketing and exceptional creative development. We unite media buying, creative development, and agency access to top-tier ad platforms to provide a powerful blend of services, expertise, and exclusive partnerships around the globe.
Our dedication to excellence and innovation is evident in every project we undertake. Our brand is anchored by our core values: reliability, mutual trust, top-tier service, steadfast commitment, and unending innovation. As we expand our horizons, Point2Web is committed to transparency, integrity, and achieving superior results for our clients.
We redefine the standard with our forward-thinking mindset and the latest in technology, setting new benchmarks in creativity. With a footprint in nine countries, advertisers and publishers worldwide can benefit from our unwavering commitment to driving their growth.
About NewsBreak
NewsBreak is the leading platform for local news and information in the United States, providing users with the local news and information they want and need in a digital form. By using cutting-edge technology that learns users’ preferences to curate tailored content for them, NewsBreak gathers community-focused news and information from over 10,000 sources in a timely, accessible, and easy-to-use way at no cost to users. NewsBreak is bridging the gap between new technology and traditional local media, offering an innovative digital solution that benefits everyone, from individual users and their communities to businesses across America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729481955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom